Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, noviembre 17
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Niagen Bioscience Inc
NAGE
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$2.00
-0.01
-0.5%
Últ. Act.: Nov 17, 12:23 PM
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Niagen Bioscience Financials
Niagen Bioscience (NAGE) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Niagen Bioscience Raises FY2026 Sales Guidance from $138.982M-$145.299M to $145.299M-$151.616M vs $130.410M Est
Niagen Bioscience (NASDAQ:NAGE) raises FY2026 sales outlook from $138.982 million-$145.299 million to $145.299 million-$151.616 million vs $130.410 million estimate.
Benzinga Newsdesk
PRO
Niagen Bioscience Q3 EPS $(0.01) Misses $0.02 Estimate, Sales $27.192M Miss $32.062M Estimate
Niagen Bioscience (NASDAQ:NAGE) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.02 by 150 percent. This is a 120 percent decrease over earnings of $0.05 per share from
Benzinga Newsdesk
PRO
Niagen Bioscience Widens FY2026 Sales Guidance of $138.982M-$145.299M vs $141.072M Est
Niagen Bioscience (NASDAQ:NAGE) widens FY2026 sales outlook from $138.982 million-$145.299 million to $138.982 million-$145.299 million vs $141.072 million estimate.
Benzinga Newsdesk
PRO
Niagen Bioscience Q2 EPS $0.01 Misses $0.02 Estimate, Sales $29.785M Miss $30.690M Estimate
Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.02 by 50 percent. This is a 75 percent decrease over earnings of $0.04 per share from the
Benzinga Newsdesk
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED)
Niagen Bioscience reaffirms 2026 sales outlook after first-quarter revenue and profit rose alongside investments in injections and skincare.
Eva Mathew
Earnings Scheduled For May 6, 2026
Benzinga Insights